Milestone Pharmaceuticals IncNASDAQ:MIST
- LAST PRICE1.8700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.8800/ 12
- Ask / Lots1.9700/ 10
- Open / Previous Close--- / 1.8700
- Day Range---
- 52 Week Range
- Volume20
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MIST |
|---|---|---|
| 09:32 ET | 1125 | 1.84 |
| 09:35 ET | 11100 | 1.855 |
| 09:44 ET | 12000 | 1.85 |
| 09:46 ET | 5343 | 1.855 |
| 09:55 ET | 15552 | 1.89 |
| 09:57 ET | 500 | 1.855 |
| 10:00 ET | 200 | 1.855 |
| 10:02 ET | 200 | 1.855 |
| 10:04 ET | 1429 | 1.855 |
| 10:06 ET | 1683 | 1.86 |
| 10:15 ET | 8240 | 1.855 |
| 10:18 ET | 1953 | 1.855 |
| 10:24 ET | 100 | 1.855 |
| 10:27 ET | 2500 | 1.845 |
| 10:31 ET | 452 | 1.855 |
| 10:33 ET | 119 | 1.855 |
| 10:38 ET | 1000 | 1.857399 |
| 10:44 ET | 3021 | 1.865 |
| 10:45 ET | 1100 | 1.87 |
| 10:47 ET | 100 | 1.87 |
| 10:51 ET | 15823 | 1.855 |
| 10:54 ET | 760 | 1.855 |
| 10:56 ET | 200 | 1.855 |
| 11:00 ET | 100 | 1.855 |
| 11:09 ET | 4826 | 1.87 |
| 11:12 ET | 6130 | 1.8577 |
| 11:21 ET | 2400 | 1.8634 |
| 11:23 ET | 940 | 1.87 |
| 11:25 ET | 1000 | 1.87 |
| 11:27 ET | 100 | 1.87 |
| 11:32 ET | 100 | 1.87 |
| 11:36 ET | 200 | 1.875 |
| 11:43 ET | 400 | 1.8706 |
| 11:50 ET | 2700 | 1.87 |
| 11:52 ET | 5200 | 1.865 |
| 12:01 ET | 1500 | 1.865 |
| 12:03 ET | 2500 | 1.862 |
| 12:06 ET | 1000 | 1.865 |
| 12:12 ET | 4000 | 1.865 |
| 12:14 ET | 1314 | 1.875 |
| 12:17 ET | 500 | 1.8742 |
| 12:19 ET | 100 | 1.875 |
| 12:24 ET | 400 | 1.875 |
| 12:26 ET | 4250 | 1.8701 |
| 12:28 ET | 5000 | 1.87 |
| 12:32 ET | 1000 | 1.875 |
| 12:46 ET | 21723 | 1.885 |
| 12:48 ET | 1000 | 1.885 |
| 12:50 ET | 5703 | 1.885 |
| 12:51 ET | 1501 | 1.885 |
| 12:55 ET | 300 | 1.8812 |
| 01:00 ET | 1796 | 1.88 |
| 01:11 ET | 474 | 1.885 |
| 01:31 ET | 4500 | 1.885 |
| 01:33 ET | 479 | 1.88 |
| 01:38 ET | 200 | 1.8806 |
| 01:44 ET | 100 | 1.88 |
| 01:45 ET | 300 | 1.885 |
| 01:51 ET | 6694 | 1.89 |
| 01:56 ET | 100 | 1.89 |
| 02:02 ET | 2100 | 1.895 |
| 02:03 ET | 2100 | 1.895 |
| 02:05 ET | 7323 | 1.895 |
| 02:07 ET | 400 | 1.9 |
| 02:14 ET | 300 | 1.9093 |
| 02:16 ET | 15218 | 1.89 |
| 02:18 ET | 1800 | 1.881 |
| 02:20 ET | 2000 | 1.8801 |
| 02:23 ET | 8881 | 1.9 |
| 02:25 ET | 1100 | 1.895 |
| 02:30 ET | 1000 | 1.89 |
| 02:32 ET | 1250 | 1.895 |
| 02:45 ET | 3500 | 1.895 |
| 02:48 ET | 200 | 1.9 |
| 02:56 ET | 100 | 1.9 |
| 02:59 ET | 600 | 1.9 |
| 03:08 ET | 200 | 1.9 |
| 03:14 ET | 2300 | 1.895 |
| 03:15 ET | 25137 | 1.89 |
| 03:17 ET | 1000 | 1.9 |
| 03:28 ET | 1100 | 1.885 |
| 03:33 ET | 303 | 1.88 |
| 03:48 ET | 13719 | 1.88 |
| 03:57 ET | 4025 | 1.875 |
| 04:00 ET | 2949 | 1.87 |
Nov 25, 2024
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference, from 8:00AM ET on Monday Nov 25, 2024 by Dow Jones
8:00AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 12, 2024
*DJ Milestone Pharmaceuticals 3Q Loss $9.44M >MIST, from 9:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
9:03AM ET on Tuesday Nov 12, 2024 by Dow JonesMilestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update, from 9:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
9:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Milestone Pharmaceuticals Inc | 98.7M | -2.3x | --- |
MediciNova Inc | 98.6M | -9.6x | --- |
Oramed Pharmaceuticals Inc | 95.5M | 23.7x | --- |
Avalo Therapeutics Inc | 99.3M | -0.9x | --- |
Renovaro Inc | 96.9M | -0.7x | --- |
Tiziana Life Sciences Ltd | 101.8M | -5.3x | --- |
Company Information
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Contact Information
- Headquarters
- 420-1111 boul. Dr.-Frederik-PhilipsMONTREAL, QC, Canada H4M 2X6
- Phone
- 514-336-0444
- Fax
- 514-336-0444
Executives
- Non-Executive Independent Chairman of the Board
- Robert Wills
- President, Chief Executive Officer, Director
- Joseph Oliveto
- Chief Financial Officer, Executive Vice President of Corporate Development
- Amit Hasija
- Chief Operating Officer
- Jeffrey Nelson
- Chief Medical Officer
- David Bharucha
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $98.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-0.81 |
Book Value | $0.50 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
